Test TSKgel UP-SW UHPLC SEC columns risk-free
Try TSKgel UP-SW columns for SEC analysis of biomolecules risk-free for 30 days
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2055 entries already.
Entries by Thomas Gabrielczyk
Infrastructure makes the difference
A well connected and effective infrastructure, a high density of research and development as well as close networking are of great value, not only to founders. Within the successful healthcare cluster Berlin-Brandenburg, these include numerous technology parks in the region. The parks offer optimal space including state of the art laboratories to start-up and grown-up companies.
Agomab Therapeutics NV raises US$100m in Series C financing
Belgian fibrosis specialist Agomab Therapeutics NV has raised US$100m to advance development of its pipeline.
AstronauTx closes £48m Series A financing
Alzheimer’s specialist AstronauTx Ltd has closed a £48m Series A financing to create new treatments for Alzheimer’s diseas
Sino Biological Announces the Opening of its New US-Based Center for Bioprocessing
Sino Biological, Inc., is pleased to announce the formal opening of its new Center for Bioprocessing (C4B) in Houston, Texas USA, adjacent to the world-renowned Texas Medical Center.
French team BioAroma awarded with BISC-E 2023 prize
At the celebration of the 10th anniversary of the Bio-based Industry Consortium (BIC), the student team BioAroma was presented with the BISC-E 2023 award, which comes with €5000 in prize money.
Orakl Oncology SA raises €3m to advance tumour modelling
Paris-based Orakl Oncology SA has raised €3m to develop its techbio platform for precision oncology.
Precision therapeutics: optimising early discovery
Precision medicine tailors therapeutics to individual patients’ diseases, and is seen as the future of clinical practice. With significant time and financial investments being made in developing therapeutics, the ultimate success of patient-data driven precision therapies hinges on three main factors: the quality of the tissue samples, the associated molecular data, and the analysis used in their development.
Sanofi licences vaccine against bacterial sepsis
French pharma major Sanofi SA will pay US$175m upfront to Janssen Pharmaceuticals, Inc. for commercialisation of a Phase III vaccine against extraintestinal pathogenic E. coli.
Spain set to unveil the potential of the biologisation of medicine and food production
The Spanish EU Council Presidency is to set the course for the internationally competitive use of biotechnology in drug development, plant breeding and food production.